SURVYR

VRTX

Vertex Pharmaceuticals
$529.69
+$8.66 (1.66%)Oct 28 close
Health CareS&P 500 CompareTechnicals
1M3M6M1Y2Y
-7%+3%+13%+23%+33%Oct 2025Oct 2026Apr 202652w high $557.9652w low $409.47
VRTXSPY
Wall St. Highest PT $723.76 (+36.6%) Wall St. Avg PT $593.25 (+12.0%)
$409$493$577$661$745POC $447Hi $724Avg $593
Underwater Drawdown %Max DD -15.2%Current -5.1%
0.0%-15.2%
Relative Strength vs SPY+12.1% vs SPYOutperforming
+23%0%-23%
1W
+$5.17 (0.99%)
1M
+$2.02 (0.38%)
3M
+$46.36 (9.59%)
6M
+$106.45 (25.15%)
YTD
+$76.33 (16.84%)
1Y
+$107.30 (25.40%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street & Morningstar coverage
Wall Street consensusNo covering analysts on file for VRTX
Analyst price targetsNo target range on file
Morningstar star ratingNot rated
Checked Wall Street & Morningstar feeds · All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

52-week range$409.47 – $557.96

What they do

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
55th percentile in sector
C+
12-1 return: +22.8%
Percentile within its GICS sector across the S&P 1500.
Growth
67th percentile in sector
B
Revenue growth (YoY): +12.5%
Percentile within its GICS sector across the S&P 1500.
Value
25th percentile in sector
D+
Forward E/P: 4.0% · EBITDA/EV: 4.2%
Percentile within its GICS sector across the S&P 1500.
Profitability
88th percentile in sector
A-
Profit margin: +35.0% · Return on equity: +23.5%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
ranked 99 of 499 · 12-month momentum 39.0%
 Momentum Blend
Not in the current book
 New Highs Growth
ranked 44 of 589 · 12-month momentum 37.7%
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

Next report: –
No EPS history available.

News & catalysts

More news
Has The Story Under Krystal Biotech Stock Run Out?
Trefis · 23h ago
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue
Nasdaq · Oct 27
The Biotech Leader Who Erased Team Lanes
The Wall Street Journal · Oct 27
Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.
Nasdaq · Oct 24
Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III
Nasdaq · Oct 23
Insider trades
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed – ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026